Emma Walmsley (pictured), CEO of GlaxoSmithKline (GSK), has launched “the most radical shake-up” of the group in 20 years, says Hannah Boland in The Daily Telegraph. The plan is to spin off GSK’s consumer-healthcare arm, “which makes toothpaste and... painkillers”, and use the cash raised to boost sales at the core business, dubbed “new GSK”.
With several drugs about to lose patent protection, the dividend will be cut, with the money saved reinvested in “a hunt for new blockbuster drugs”. Walmsley is under increasing pressure, says Boland in The Sunday Times. Since 2017 she has “slashed” poorly performing drug programmes, revamped management and “pushed the drugmaker back into oncology”. But this has not satisfied investors irked by GSK’s “perennial underperformance”.
Some want new leadership, while the decision of activist fund Elliott Management to take a stake in GSK is another challenge to her authority. Those calling for “radical change” at GSK are likely to be disappointed by this latest “fudge”, says Lex in the Financial Times. Walmsley’s promise that GSK will “coalesce around core pharma” is undermined by the fact that even after the hived-off consumer unit is listed, GSK will retain up to 20% of the new company.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
This in turn “reduces the kitty earmarked for dealmaking and research and development”. While this “vacillating” is “understandable”, as blockbuster drugs “take a long time to come to market”, Walmsley’s plan won’t “quieten those calling for her resignation”.
-
New Chase bonus deal takes savings rate to 4.75% – is it worth it?Chase’s latest savings deal propels it into first place in the best-buy tables, but there are some pitfalls to look out for
-
Review: Trasierra – a yoga retreat in the Spanish hillsFlora Connell joins a yoga retreat at Trasierra, in the Sierra Morena mountains north of Seville
-
Why CEOs deserve a pay riseOpinion The CEOs of big companies often come under fire for being grossly overpaid. But the truth, as per some economists, is the opposite. Do they merit a pay rise?
-
Rolls-Royce stock jumps 15% – could it climb further?Aircraft-engine group Rolls-Royce’s CEO has been hailed as a hero for spearheading the firm’s recovery. And the future looks bright, says Matthew Partridge
-
The power of private marketsInterview Helen Steers, co-manager of the Pantheon International investment trust, tells MoneyWeek about the vast array of compelling opportunities in private equity
-
Vertex Pharmaceuticals is an uncommon opportunity in rare diseasesVertex Pharmaceuticals operates in a profitable subsector and is poised for further success
-
Global investors have overlooked these top tips in emerging marketsOpinion Chris Tennant, co-portfolio manager of Fidelity Emerging Markets, picks three attractive companies in emerging markets
-
King Coal has not been dethroned yet — should you buy?The demand for coal is only growing, yet investors don’t seem to want to take advantage of the opportunity, says Rupert Hargreaves
-
It’s time to start buying Europe again, says Merryn Somerset WebbOpinion Europe's stocks are cheap and the economic backdrop is starting to look cheerier, says Merryn Somerset Webb
-
Prosus to buy Just Eat for €4.1 billion as takeaway boom fadesFood-delivery platform Just Eat has been gobbled up by a Dutch rival. Now there could be further consolidation in the sector
